Skip to contentX
Xenon Pharmaceuticals Inc.
X
XENEXenon Pharmaceuticals Inc. Q2 2026 · 10-Q
Revenue$0.00$0.00— vs Q2 2025 Net Income-$110.74M-$110.74MN/M vs Q2 2025 EPS Diluted-$1.11-$1.11N/M vs Q2 2025 Operating Income-$123,155,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Xenon Pharmaceuticals Inc. · CIK 1582313 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$95,665,000N/M ended Jun 30, 2026 · filed Aug 6, 2026 · 37 d after period end